A decoy mutant ACE2 designed to reduce COVID-19

Mazharul Maishan; Diana L Lim; Guy A Zimmerman; Michael A Matthay

doi:10.1016/j.tips.2022.02.010

A decoy mutant ACE2 designed to reduce COVID-19

Trends Pharmacol Sci. 2022 Sep;43(9):703-705. doi: 10.1016/j.tips.2022.02.010. Epub 2022 Feb 28.

Authors

Mazharul Maishan¹, Diana L Lim², Guy A Zimmerman³, Michael A Matthay⁴

Affiliations

¹ Cardiovascular Research Institute, University of California at San Francisco, San Francisco, CA, USA.
² Molecular Medicine Program, University of Utah Health, Salt Lake City, UT, USA.
³ Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
⁴ Cardiovascular Research Institute, University of California at San Francisco, San Francisco, CA, USA; Departments of Medicine and Anesthesia, University of California at San Francisco, San Francisco, CA, USA. Electronic address: michael.matthay@ucsf.edu.

Abstract

The need for new coronavirus disease 2019 (COVID-19) therapeutic strategies continues, especially as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge. Zhang and colleagues elegantly engineered a mutant angiotensin-converting enzyme 2 (ACE2) that competitively binds SARS-CoV-2 spike protein, reduces viral uptake by human lung cells, and ameliorates SARS-CoV-2-induced lung injury in mice expressing human ACE2.

Keywords: ARDS; COVID-19 therapy; viral pneumonia.

Publication types

Comment

MeSH terms

Angiotensin-Converting Enzyme 2* / genetics
Angiotensin-Converting Enzyme 2* / metabolism
Animals
COVID-19* / prevention & control
Humans
Mice
Protein Engineering
SARS-CoV-2
Spike Glycoprotein, Coronavirus* / metabolism

Substances

Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Angiotensin-Converting Enzyme 2